Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine, pregabalin and combination therapy for idiopathic overactive bladder
2005-004249-33Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tolterodine and pregabalin in overactive bladder (OAB) (4 arms), sponsored by Pfizer. Primary endpoint: Change in mean voided volume per micturition at 4 weeks. Started Oct 2005; status: completed.
02
Drugs
tolterodinepregabalin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-004249-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004249-33.